UT/Lung more worried about Cafepharma than OIG?

[Anonymous]

Is there a newly-created EVP position?

 

[Anonymous]

Is there a newly-created EVP position?

Based on number of replies, i'd say more worried about OIG, IDGIT!!! And rightfully so.

 

[Anonymous]

Who's the "IDGIT?" Posts on other threads are being removed by people who should've never guided this publicly-traded company toward a government investigation for fraudulently taking taxpayer $.

 

[Anonymous]

Who's the "IDGIT?" Posts on other threads are being removed by people who should've never guided this publicly-traded company toward a government investigation for fraudulently taking taxpayer $.

The govt investigation is because of marketing practices to grow sales of products in an orphan disease. To reach the sales goals has required off label marketing and very questionable business practices by BOTH Lung and UT. Deal with it.

 

[Anonymous]

Yes, OIG is here to deal w UT/Lung top 1%-ers who should be more concerned about pleading the 5th than others' exercise of 1st Amendment rights.

 

[Anonymous]

Lung VP of sales counted all scripts as revenue and reported to board, that's what the OIG should know.

 

[Anonymous]

Good thing they have that billion $ cash account for fines!

 

[Anonymous]

?

 

[Anonymous]

What Will United Therapeutics do With Over $1 Billion in Cash?

Mar 6 2014 - 11:58am
MBM

Silver Spring-based United Therapeutics (NASDAQ: UTHR) finished off 2013 with a strong showing, collecting revenues of over $1.1 billion for the first time in its corporate history as well posting a net profit for the full-year 2013 and upbeat 2014 outlook.

Hidden beneath all the earnings news is a very important line segment on the balance sheet called “Cash and Cash Equivalents”. These are assets that have high liquidity and can be easily converted to cash or are cash themselves; that being said United Therapeutics has amassed nearly $1.14 billion worth of it. The amount is over $350 million more than the company held at the end of 2012.

So what will United Therapeutics do with all that cash? Besides holding it for a rainy day, it’s investing in the future. While the downtown Silver Spring headquarter campus is currently undergoing an expansion, CEO Martine Rothblatt J.D., Ph.D., noted during the company’s conference call that a possible strategy would be to use the funds to make acquisitions. Meaning it could arrange a license agreement, acquire patents or buyout a sizable biotech. With pressure from generic drug makers on its biggest revenue makers Remodulin, an acquisition of another biotech would be a smart move that could further diversify its portfolio of drugs on the market. Regardless United Therapeutics is already making that push, well on its way into neurologic cancer and viral treatments.**

 

[Anonymous]

Well, they could use all this extra cash to wipe away all the waste that encapsulates their minds and GI tract!